Can I Take Green Tea Extract (EGCG) with Cialis (Tadalafil)?

What Happens Pharmacologically When You Combine EGCG and Tadalafil?

The core interaction between green tea extract and tadalafil is pharmacokinetic, not pharmacodynamic. EGCG inhibits cytochrome P450 3A4 (CYP3A4), the primary hepatic enzyme responsible for metabolizing tadalafil. When CYP3A4 activity drops, tadalafil clearance slows, plasma concentrations rise, and the duration of drug effect extends beyond its labeled 17.5-hour half-life [1].

Tadalafil's prescribing information explicitly flags CYP3A4 inhibitors. Ketoconazole 400 mg daily, a strong CYP3A4 inhibitor, increased tadalafil AUC by 312% in a formal pharmacokinetic study cited in the FDA label [2]. EGCG is a weaker inhibitor by comparison, but the direction of effect is the same.

CYP3A4 Inhibition: How Strong Is EGCG?

Published in vitro data characterize EGCG as a moderate-to-weak CYP3A4 inhibitor depending on concentration. A 2010 study in Drug Metabolism and Disposition found that EGCG inhibited CYP3A4 with an IC50 of roughly 100 to 200 micromolar in human liver microsomes [3]. At doses achievable from food-grade green tea beverages (50 to 100 mg EGCG per cup), plasma concentrations rarely approach that threshold. High-dose capsule extracts delivering 400 to 800 mg EGCG per serving shift the calculation meaningfully.

What This Means for Tadalafil Plasma Levels

Even a 20 to 30% increase in tadalafil AUC from moderate CYP3A4 inhibition could extend the drug's vasodilatory effects. For most men taking 10 to 20 mg as-needed, this might prolong mild side effects such as headache, flushing, or nasal congestion. For men on 5 mg daily dosing with pre-existing cardiovascular disease or taking alpha-blockers, prolonged hypotensive effects carry more clinical weight [4].

The Second Pathway: P-glycoprotein

EGCG also inhibits P-glycoprotein (P-gp), an efflux transporter that limits drug absorption in the gut. A study in Molecular Nutrition and Food Research demonstrated that EGCG reduced P-gp-mediated drug efflux in Caco-2 intestinal cell models [5]. Tadalafil is a P-gp substrate. Inhibiting P-gp increases intestinal absorption, which adds to whatever CYP3A4 inhibition is already occurring, compounding the net exposure increase.

Hepatotoxicity: The More Pressing Clinical Concern

Beyond the pharmacokinetic overlap, concentrated green tea extract carries its own liver-injury profile independent of tadalafil. The FDA has received MedWatch reports linking high-dose green tea extract supplements to hepatocellular injury, including cases requiring liver transplantation [6]. Tadalafil itself is not a known hepatotoxin at therapeutic doses, but any additive metabolic burden on the liver is worth accounting for.

What the Case Reports Show

A 2020 systematic review published in Liver International identified 80 published case reports of liver injury attributed to green tea extract supplements [7]. Median daily EGCG dose in those cases was approximately 704 mg. Most cases resolved after stopping the supplement, but a subset progressed to acute liver failure. The latency from supplement initiation to symptom onset ranged from 2 weeks to 12 months, making causal attribution difficult without objective causality scoring.

USP and NIH Guidance on Safe EGCG Dosing

The National Institutes of Health Office of Dietary Supplements has noted that doses of green tea extract providing more than 800 mg EGCG per day are associated with hepatotoxicity signals and recommends that consumers not exceed that threshold [8]. The United States Pharmacopeia has proposed a cautionary label stating: "Not to be used if you have liver disease. Discontinue use and consult a health care practitioner if you develop symptoms of liver trouble." [9]

Tadalafil's Own Hepatic Metabolism

Tadalafil undergoes extensive hepatic first-pass metabolism via CYP3A4 to its inactive catechol glucuronide metabolite. In patients with mild-to-moderate hepatic impairment (Child-Pugh Class A or B), tadalafil AUC increases and the FDA label recommends a maximum dose of 10 mg as-needed with no more than once-daily use [2]. Adding a hepatotoxic supplement to a drug with hepatic-impairment dosing restrictions creates a double exposure risk that few clinicians would accept without close monitoring.

Does the Form of Green Tea Matter? Beverage vs. Extract

The form of green tea consumed makes a significant practical difference. Brewed green tea delivers 50 to 150 mg of total catechins per 240 mL cup, of which EGCG comprises roughly 60 to 65% [10]. To reach the 700 mg EGCG threshold associated with hepatotoxicity in case reports, a person would need to drink 7 to 10 cups per day consistently, an unlikely scenario for most supplement users.

Capsule Extracts and Dose Concentration Risk

Capsule-form green tea extracts marketed for weight loss or antioxidant benefit commonly deliver 400 to 750 mg EGCG per serving, sometimes twice daily. A single serving can match what a moderate tea drinker consumes across an entire week. This concentration difference is why the FDA's MedWatch hepatotoxicity signal clusters around supplement use rather than beverage consumption [6].

Standardized Extracts vs. Non-Standardized Products

Many over-the-counter green tea supplements do not standardize their EGCG content accurately. A 2015 analysis in Journal of AOAC International tested 20 commercially available green tea supplements and found EGCG content ranged from 11% to 86% of the label claim, with some products delivering nearly double the stated dose [11]. For a patient already on a narrow-therapeutic-window drug like tadalafil, this variability adds measurable unpredictability to any interaction risk estimate.

Clinical Monitoring: What to Watch For

If a patient discloses concurrent use of both tadalafil and a concentrated green tea extract, a reasonable clinical response involves three actions: dose assessment, baseline labs, and symptom review at follow-up.

Liver Function Monitoring

Baseline ALT and AST levels provide a reference point before introducing or continuing high-dose green tea extract. The American College of Gastroenterology's 2014 clinical guideline on drug-induced liver injury suggests repeating liver chemistries within 4 to 6 weeks of starting any agent with a known hepatotoxicity signal [12]. An ALT rise above 3 times the upper limit of normal warrants stopping the supplement and re-testing within 2 weeks.

Tadalafil Side Effect Surveillance

Any increase in tadalafil-associated side effects, particularly prolonged headache, persistent flushing lasting more than 6 hours, or symptomatic hypotension, may signal elevated drug plasma levels from reduced CYP3A4 clearance. Men using tadalafil 20 mg as-needed who begin a high-dose green tea extract cycle should be counseled to consider dropping to the 10 mg dose until the interaction profile is better understood in their individual case [2].

Drug Interaction Databases

The Natural Medicines Comprehensive Database rates the tadalafil-green tea extract interaction as "possibly unsafe" based on the combined hepatotoxicity and CYP3A4 inhibition concerns [13]. The interaction is not listed as an absolute contraindication, which means shared decision-making with a clinician, rather than categorical avoidance, is the appropriate framework.

Who Is at Highest Risk from This Combination?

Not every man on tadalafil faces identical risk from green tea extract. Several clinical variables sharpen or blunt the concern.

Patients With Pre-Existing Liver Conditions

Any degree of hepatic fibrosis, fatty liver disease, or elevated baseline transaminases increases the probability that high-dose EGCG tips the liver into clinically significant injury. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the global adult population, according to a 2018 meta-analysis in the Journal of Hepatology [14]. A substantial portion of men seeking tadalafil for ED also carry metabolic syndrome, which overlaps heavily with NAFLD.

Men on Multiple CYP3A4 Substrates or Inhibitors

Tadalafil is not the only CYP3A4 substrate many men take. Statins (particularly simvastatin and atorvastatin), certain calcium channel blockers, and alpha-blockers like tamsulosin all interact with CYP3A4 to varying degrees. Stacking EGCG-mediated CYP3A4 inhibition on top of an already-congested enzyme pathway multiplies the chance of drug-level surprises across the whole medication list [15].

Daily-Dose Tadalafil vs. As-Needed Use

Men on 5 mg daily tadalafil have a continuously present drug load. Even a modest 20 to 25% increase in AUC from EGCG accumulates over days and weeks, unlike the transient exposure spike that might follow a single as-needed 20 mg dose. The compounding nature of daily dosing makes the CYP3A4 interaction more clinically relevant in this population.

Practical Guidance for Patients Already Taking Both

Some men reading this article are already combining tadalafil with green tea extract. The guidance differs by supplement dose.

If You Are Using Brewed Green Tea Beverages

One to three cups of brewed green tea daily is unlikely to produce clinically meaningful CYP3A4 inhibition or hepatotoxic stress in otherwise healthy individuals. No dose adjustment to tadalafil is typically warranted. Disclosure to your clinician remains advisable, but urgency is low at this intake level [10].

If You Are Using a Capsule Extract at 400 mg EGCG or Above

Disclose this to your prescribing provider before your next refill. Request baseline liver function tests (ALT, AST, total bilirubin) if they are not current within the past six months. Monitor for prolonged tadalafil side effects. If your extract delivers 700 mg EGCG or more per day, consider switching to a lower-dose formulation or returning to beverage-form green tea while remaining on tadalafil [8].

If You Develop Any Symptoms of Liver Stress

Symptoms including right upper quadrant discomfort, dark urine, jaundice, or unexplained fatigue while taking any high-dose botanical supplement require same-day contact with a clinician and immediate suspension of the supplement. These symptoms map onto the prodrome of drug-induced liver injury described in the LiverTox database maintained by the National Library of Medicine [16].

What the Evidence Does Not Yet Answer

The literature contains no randomized controlled trial directly examining EGCG co-administration with tadalafil in humans. The interaction framework above is constructed from mechanistic pharmacology data, case reports, and single-drug pharmacokinetic studies. That gap means the true magnitude of tadalafil AUC change from real-world EGCG supplementation remains uncertain. A formal crossover study measuring tadalafil plasma levels with and without 400 mg EGCG supplementation would resolve the question far more precisely than current inference allows.

The absence of direct trial data does not equal absence of risk. It means the risk estimate carries wider confidence intervals than a clinician would prefer when counseling patients.